ReShape Medical, Inc. Completes Offering of Its Series D Preferred Stock, Raising $38 Million

ReShape Medical, Inc.

Stradling client ReShape Medical, Inc. completed an offering of its Series D Preferred Stock to existing and new investors, including lead investor HealthCor Partners, for a total purchase price of approximately $38 million.

ReShape Medical is a private, venture-financed medical device company based in San Clemente, California, that recently received FDA approval for its ReShape Integrated Dual Balloon System. The ReShape Integrated Dual Balloon System is a first-of-its-kind non-surgical weight loss procedure for people who either do not want or do not qualify for bariatric surgery.

The Newport Beach-based team representing ReShape includes Bruce Feuchter and Jeff Estes.